USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Technology Advances in Senolytics
Technology Advances in Senolytics
Innovative Drug Development Culture Working to Prolong Health Spans and Eliminate Aging Cells
02-May-2023
Global
Description
Senolytics is a relatively new field of development that falls under the broad category of senotherapeutics, along with senomorphics and senostatics. Although nascent, the field could address the root causes of most chronic conditions brought on by aging as it clears senescent cells that have ceased to multiply (and ideally are eliminated from the body) but remain metabolically active after a senescence-associated secretory phenotype (SASP) change, which leads to disease conditions.
The youngest baby boomers will be over the age of 65 in 2029, just 6 years away, which suggests an expanding economic burden related to this population, considering the cost of healthcare, caregivers, palliative care, health insurance, and other care-related activities. This wave of baby boomers makes it essential to address chronic diseases at their onset through senotherapeutics, with senolytics being such a method.
Senotherapeutic drug development suffered a few minor hiccups in the early days of research. For instance, in 2020, one new drug failed at inception after investors had contributed significant funding. However, constant research has resulted in a few possible opportunities that have rekindled interest in this area. It is imperative to track developments in this space to understand the progress of pharmaceuticals, nutraceuticals, and other emerging opportunities. This is a compelling space to watch for investments and research.
This research identifies the various drugs, modalities, development approaches, technology advancements, nutraceutical growth, opportunities for their translation to over-the counter (OTC) treatments, as well as the challenges that still require addressing. In addition, the study highlights the immediate R&D needs and innovations likely to emerge in the next 5 years, and it sheds light on developments regarding mergers and acquisitions (M&As), partnerships, licensing, funding, and opportunity areas for growth.
RESEARCH: INFOGRAPHIC
This infographic presents a brief overview of the research, and highlights the key topics discussed in it.Click image to view it in full size
Table of Contents
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Senolytics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Research Context and Scope of Analysis
Segmentation
Growth Drivers
Growth Restraints
The Need for Senotherapeutics
Senolytics Are Emerging as a Promising Class of Senotherapeutics
Benefits of Senolytics over Other Senotherapeutics
Senolytic Drug Development Timeline
Senolytics—A Novel Approach to Healthcare, Presents Interesting Opportunities and Challenges
Successes, Opportunities, and Failures in Senolytic Drug Discovery
Promising R&D Prospects in Senolytics
Things to Know about Senolytic Drug Development
Approaches to Target Sncs Increase R&D Opportunities and Success Possibilities
Targets, Drugs, and Modalities under Investigation to Develop Senolytic Drugs
Anti-apoptotic Pathways Are a Highly Explored Area for Senolytics
Targeting Anti-apoptotic Pathways Is a Common Approach to Senolytic Drugs
Tackling Newer Targets Is an Emerging Approach
Therapies Targeting Various Physiologies and Pathways
Small Molecule Senolytics
Biologics under Development for Senolytics
Cell and Gene Therapies under Development for Senolytics
Approaches to Improve the Senolytic Drug Development Process
Players in the Senolytic Drug Development Field
Natural Products Can Potentially Translate to Senolytics
Naturally Derived Senolytics and Commercial Developments
Opportunities and Recent Advancements in Naturally Derived Senolytics
Continuous Innovations Will Shape the Senolytic Drug Development Industry during the Next 5 Years
Outlook for Senolytic Drug Development
Senolytic Drug Technology Enablers
Emerging Technologies for Senolytic Drug Development and Diagnostics
Biomarkers Play a Vital Role in the Senotherapeutic Industry
Efforts to Discover a Universal SNC Biomarker
AI-assisted Advances in Drug Discovery and Diagnostics
Financial Growth, M&As, Partnership Trends, and New Entrants Are Evident in the Young Field of Senolytics
A Conducive Funding Environment, an Active R&D Space, and the Significant Contribution of AI Drive Senolytic Drug Development
Completed M&As and Proposed Mergers to Look Forward to in 2023
Partnerships in Senolytic Drug Discovery and Development Skew Toward AI
Partnerships in Senolytic Drug Discovery and Development Skew Toward AI (continued)
Drug and Technology Licensing and IPOs by Senolytic Developing Companies Will Increase
Spin-off Companies Developing Senolytic Drugs Are on the Increase
Conducive Grants and Research Funding Support Senotherapeutics
Funding Analysis in the Senolytic Drug Development Industry
Growth Opportunity 1: Growing Involvement of Large Pharma Companies
Growth Opportunity 1: Growing Involvement of Large Pharma Companies (continued)
Growth Opportunity 2: Development of New Biomarkers to Aid in Drug Discovery
Growth Opportunity 2: Development of New Biomarkers to Aid in Drug Discovery (continued)
Growth Opportunity 3: Convergence Opportunities Between Drug Development Companies
Growth Opportunity 3: Convergence Opportunities Between Drug Development Companies (continued)
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
| Author | Lonita lawrence |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Senolytics Market |
| Keyword 2 | Technology Advances in Senolytics |
| Keyword 3 | Senotherapeutic drug development |
| Podcast | No |
| WIP Number | DA8D-01-00-00-00 |